Hourly refreshTue, Oct 27, 2026

Press Release Database

Recent press releases, indexed by topic.
Topic

Biotech & pharma

2,247 press releases in English indexed under biotech & pharma.

Clear all filters
Keywords, dates and language
Sources
up to 10
Newswires (50)
Company newsrooms (91)
Companies
Releases linked to any of up to 10 companies
AllFinanceCryptoAISaaSHealthcareReal estateEnergyRetailAutomotiveGamingMediaEducation
+ 33 more topics
TelecomTravelFood & drinkFashion & luxurySportsIndustrialAerospace & defenseLogisticsBiotech & pharmaCybersecuritySemiconductorsSustainabilityBankingInsuranceInvesting & marketsPayments & fintechLegalGovernment & policyNonprofitsJobs & workplaceMarketing & advertisingSoftware & ITCloud & data centersInternet & appsConsumer electronicsConsumer goodsEntertainmentMedical devicesConstruction & engineeringChemicals & materialsMining & metalsOil & gasAgriculture
DownloadExcelTXT
Biotech & pharma

Exosome Therapies Market Poised for Significant Growth Through 2036 as Expanding Target Populations and Biopharma Innovation Create New Opportunities

Exosome therapies offer broad regenerative and targeted-delivery potential, while standardization, scalability and regulatory hurdles create key innovation opportunities. Exosome therapies offer broad regenerative and targeted-delivery potential, while standardization, scalability and regulatory hurdles create key innovation opportunities.

Sep 14 · 09:14GlobeNewswire
Finance · Healthcare

BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients

MAINZ, Germany, and ROCKVILLE, USA, September 14, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and OncoC4, Inc. (“OncoC4”) today announced the first median overall survival (“OS”) data from the non-pivotal stage 1 of the global randomized PRESERVE-003 Phase 3 clinical trial (NCT05671510) of gotistobart (also known as BNT316 or ONC-392), in patients with squamous non-small lung cancer (“NSCLC”) whose disease progressed on prior immunotherapy and chemotherapy. Gotistobart is an investigational CTLA-4-targeting immunotherapy designed to selectively deplete regulatory T cells (“Tregs”) within the tumor microenvironment and restore anti-tumor immune activity.

Sep 14 · 08:00GlobeNewswire
Healthcare · Biotech & pharma

Tomonari Abe, President of Abe Yoando Pharma, Selected as First Japanese Speaker at Longevity Investors Conference 2026 in Switzerland

- Head of 295-year-old Japanese Pharmaceutical Pioneer to Present Asia's Longevity Growth Strategies and Bioscientific Research Initiatives at Prestigious Conference - TOKYO and GSTAAD, Switzerland, Sept. 14, 2026 -- Abe Yoando Pharma Co., Ltd., a nearly 300-year-old...

Sep 14 · 06:00PR Newswire
Biotech & pharma

NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung Cancer

Data presented at the IASLC 2026 World Conference on Lung Cancer

Sep 14 · 06:00GlobeNewswire
SaaS · Healthcare

Avacta Appoints Mats Blom to the Board of Directors as Chair of Audit Committee

LONDON and PHILADELPHIA, Sept. 14, 2026 -- Avacta Therapeutics (AIM: AVCT), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, today announced the appointment of the seasoned biotech executive Mr. Mats Blom as a member of its Board of Directors and Chair of the Audit Committee.

Sep 14 · 06:00GlobeNewswire
Healthcare · Biotech & pharma

Antengene Publishes Preclinical Research Paper on CD73 Small Molecule Inhibitor ATG-037 Combined with Selinexor in Cancer Gene Therapy

SHANGHAI and HONG KONG, Sept. 14, 2026 -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for...

Sep 14 · 04:26PR Newswire
Biotech & pharma

Accro Bioscience Announces Inclusion of AC-101 tablets in the NMPA CDE's "Caring Plan-Extension" Pilot Program for Rare Disease Drug Development

NEW YORK and SUZHOU, China, Sept. 13, 2026 -- On September 14, 2026 (China Standard Time, UTC+8), Accro Bioscience announced that AC-101 tablets have been included in the Rare Diseases Innovative Drug Development Encouragement Pilot Program (the "Caring Plan-Extension", known...

Sep 14 · 02:00PR Newswire
Biotech & pharma

Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026

PTK7 Expression Remained Stable Following Standard-of-Care Therapies, Supporting Its Relevance as a Target in Second- or Later-Line EGFR NSCLC Findings Reinforce the Scientific Rationale for HWK-007, Whitehawk's Next-Generation PTK7-Directed ADC Currently in Phase 1 Development...

Sep 14 · 01:30PR Newswire
Finance · Biotech & pharma

Capricor Deadline: CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit

NEW YORK, Sept. 13, 2026 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17, 2025 and July 26, 2026, inclusive (the "Class Period"), of the important September 28, 2026 lead...

Sep 13 · 19:53PR Newswire
Biotech & pharma

Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

New class action for Regeneron (REGN) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 9/14/2026

Sep 13 · 16:00GlobeNewswire
Biotech & pharma

Bronstein, Gewirtz & Grossman LLC Urges Capricor Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

New class action for Capricor (CAPR) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 9/28/2026

Sep 13 · 16:00GlobeNewswire
Finance · Biotech & pharma

CAPRICOR DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CAPR

NEW YORK, Sept. 13, 2026 -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17, 2025 and July 26, 2026, inclusive (the “Class Period”), of the important September 28, 2026 lead plaintiff deadline.

Sep 13 · 14:20GlobeNewswire